TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37505117

Group type: COMPARATOR
Intervention: Ever smoking
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Increasing number of pack-years
Number of subjects: 576
Study: 37505258

Group type: EXPERIMENTAL
Intervention: Postoperative acute kidney injury (PO-AKI)
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 10568

Group type: COMPARATOR
Intervention: ICU mortality
Number of subjects: 10568

Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 10568

Group type: COMPARATOR
Intervention: ICU length of stay
Number of subjects: 10568

Group type: COMPARATOR
Intervention: Hospital length of stay
Number of subjects: 10568
Study: 37505337

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 3680
Study: 37505379

Group type: EXPERIMENTAL
Intervention: Biopsy combined with LITT
Number of subjects: 15

Group type: COMPARATOR
Intervention: Biopsy alone
Number of subjects: 15
Study: 37505393

Group type: EXPERIMENTAL
Intervention: Exit interviews with MLP, CLP, and LPP patients
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Independent qualitative interviews with CLP patients
Number of subjects: 26
Study: 37505401

Group type: EXPERIMENTAL
Intervention: Former preterm birth and/or ELBW infants
Number of subjects: 304

Group type: COMPARATOR
Intervention: Full-term infants (control group)
Number of subjects: 304
Study: 37505420

Group type: EXPERIMENTAL
Intervention: Small-volume tubes
Number of subjects: 369

Group type: COMPARATOR
Intervention: Standard-volume tubes
Number of subjects: 369
Study: 37505794

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) in frontline regimens for high-risk disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) and checkpoint inhibitor therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Bv/nivolumab
Number of subjects: 0
Study: 37506059

Group type: EXPERIMENTAL
Intervention: Music with tapping
Number of subjects: 59

Group type: COMPARATOR
Intervention: Silence without tapping
Number of subjects: 59

Group type: COMPARATOR
Intervention: Simply tapping without music
Number of subjects: 59
Study: 37506163

Group type: EXPERIMENTAL
Intervention: INTER-ACT postpartum lifestyle intervention (4 face-to-face coaching sessions, supported by an e-health app)
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 1047
Study: 37506264

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 234

Group type: COMPARATOR
Intervention: Investigator-assigned standard therapy (IAT)
Number of subjects: 234
Study: 37506329

Group type: EXPERIMENTAL
Intervention: COMBO300
Number of subjects: 258

Group type: COMPARATOR
Intervention: ENCO300 (parts 1 and 2 combined)
Number of subjects: 258

Group type: COMPARATOR
Intervention: ENCO300 (part 2)
Number of subjects: 258
Study: 37506339

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone (RD)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone plus ixazomib (IRD)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: RD maintenance therapy
Number of subjects: 332
Study: 37506346

Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus Obinutuzumab (ZO)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Obinutuzumab (O)
Number of subjects: 217
Study: 37506513

Group type: EXPERIMENTAL
Intervention: IDS complete deletions/large rearrangements (n=7)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Complete deletions/large rearrangements (n=4)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Splice site variants (n=4)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Unclassifiable variants (n=3)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Splice site variants (n=5)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Overall population (n=88)
Number of subjects: 88
Study: 37506557

Group type: EXPERIMENTAL
Intervention: T-cell vaccine combined with romidepsin (RMD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Anti-CD33 antibody
Number of subjects: 11
Study: 37506588

Group type: EXPERIMENTAL
Intervention: Tipapkinogene sovacivec (TG4001) in combination with avelumab, administered subcutaneously at two dose levels weekly for 6 weeks, then every 2 weeks until 6 months, thereafter every 12 weeks.
Number of subjects: 43
Study: 37506599

Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks with ideal compliance
Number of subjects: 130
Study: 37506747

Group type: EXPERIMENTAL
Intervention: Faster heart rate
Number of subjects: 0
Study: 37506846

Group type: EXPERIMENTAL
Intervention: benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: commercially insured patients
Number of subjects: 2117
Study: 37506972

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: TVF-first event
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Non-TVF-first event
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 1498
Study: 37506974

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (BF)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Exclusive formula feeding (FF)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lactobacillus (in BF group)
Number of subjects: 115
Study: 37507196

Group type: EXPERIMENTAL
Intervention: Deep Convolutional Neural Network (DCNN) model using ResNet-50 architecture
Number of subjects: 6784

Group type: COMPARATOR
Intervention: Deep Convolutional Neural Network (DCNN) model
Number of subjects: 6784
Study: 37507274

Group type: EXPERIMENTAL
Intervention: Two doses of BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 1758

Group type: COMPARATOR
Intervention: Control group (unvaccinated or vaccinated with other vaccines)
Number of subjects: 1758
Study: 37507392

Group type: EXPERIMENTAL
Intervention: Low-dose ARVAC CG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose ARVAC CG
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNT162b2 (control group)
Number of subjects: 0
Study: 37507425

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily for a median of 14 days)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 184
Study: 37507427

Group type: EXPERIMENTAL
Intervention: Acute exacerbation of COPD requiring hospitalization
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Physical activity during hospitalization and recovery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group with stable COPD
Number of subjects: 121
Study: 37507543

Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, or both in combination with chemotherapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 41
Study: 37507580

Group type: EXPERIMENTAL
Intervention: Retinal Vessel Analysis (RVA) in PCS patients
Number of subjects: 41
Study: 37507657

Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg twice daily (14 days on/14 days off) plus nivolumab 3 mg/kg (IV every 2 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study: 37507667

Group type: EXPERIMENTAL
Intervention: Volunteer-led online group seated strength exercises using resistance bands, once weekly for 6 months
Number of subjects: 30
Study: 37507692

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: DASH diet combined with other interventions (exercise, smoking cessation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-pharmacological dietary interventions
Number of subjects: 39
Study: 37507720

Group type: COMPARATOR
Intervention: Usual Implementation (UI)
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Enhanced Supervision (ES)
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Community-Engaged Learning Collaborative (CELC)
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: All groups (UI, ES, CELC)
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: CHS staff and non-CHS staff
Number of subjects: 1296
Study: 37507763

Group type: EXPERIMENTAL
Intervention: Nitrate-replete beetroot juice (400 mg nitrate/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 60
Study: 37507772

Group type: EXPERIMENTAL
Intervention: In-home decluttering led by a social services team for 10 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study: 37507802

Group type: EXPERIMENTAL
Intervention: XL102
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: XL102 with Venetoclax
Number of subjects: 54
Study: 37508596

Group type: EXPERIMENTAL
Intervention: Parent-led memory-reframing intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 37508992

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) coupled with language therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37509027

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Portable near-infrared spectroscopy (NIRS) measures
Number of subjects: 0
Study: 37509349

Group type: EXPERIMENTAL
Intervention: Canady Helios Cold Plasma (CHCP) treatment during surgical resection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (surgical resection without CHCP)
Number of subjects: 20
Study: 37509587

Group type: EXPERIMENTAL
Intervention: GABA alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GABA/GAD65-alum treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37510718

Group type: EXPERIMENTAL
Intervention: Low-risk group (n=74)
Number of subjects: 277

Group type: COMPARATOR
Intervention: High-risk group (n=203)
Number of subjects: 277
Study: 37510828

Group type: EXPERIMENTAL
Intervention: Telemonitoring of ECG repolarization markers
Number of subjects: 215
Study: 37510953

Group type: EXPERIMENTAL
Intervention: Single-strain probiotic formulations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37510965

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 37511184

Group type: EXPERIMENTAL
Intervention: whey-based extensively hydrolyzed formula (EHF) supplemented with 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 194
Study: 37511562

Group type: EXPERIMENTAL
Intervention: CAR-T therapy (Yescarta™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 37511870

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISCHEMIA study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISCHEMIA sub-analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISCHEMIA-CKD substudy
Number of subjects: 0
Study: 37512932

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic OMNi-BiOTiC
Number of subjects: 0
Study: 37513677

Group type: EXPERIMENTAL
Intervention: MFGM-enriched milk beverage (MEB) (2.3 g/d milk phospholipids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator beverage (COMP) formulated with soy phospholipid and palm/coconut oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MFGM-enriched milk beverage (MEB)
Number of subjects: 0
Study: 37513930

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 201
Study: 37515050

Group type: EXPERIMENTAL
Intervention: TURKOVAC
Number of subjects: 190

Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Both TURKOVAC and CoronaVac
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Single booster dose
Number of subjects: 190
Study: 37515194

Group type: EXPERIMENTAL
Intervention: 500 mg of probenecid every 12 h for five days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1000 mg of probenecid every 12 h for five days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo every 12 h for five days
Number of subjects: 75
Study: 37515446

Group type: EXPERIMENTAL
Intervention: RF toothbrush
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (sham toothbrush)
Number of subjects: 58
Study: 37515459

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) therapy within 6 hours of symptom onset
Number of subjects: 456

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) therapy
Number of subjects: 456
Study: 37515636

Group type: EXPERIMENTAL
Intervention: Vestibular function evaluation by video head impulse testing
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: COMPASS 31 questionnaire for autonomic neuropathy
Number of subjects: 114
Study: 37515943

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C, selenium, zinc, vitamin E, β-carotene) for 3 to 6 months
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo for 3 to 6 months
Number of subjects: 41
Study: 37516125

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg twice a day
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once a day
Number of subjects: 778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study: 37516163

Group type: EXPERIMENTAL
Intervention: CBT-I (Cognitive Behavioral Therapy for Insomnia)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: CBT-D (Cognitive Behavioral Therapy for Depression)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: CBT-I + D (sequential intervention)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: CBT-D + I (sequential intervention)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Mood monitoring (control condition)
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: IIR predicted optimal intervention
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: One of the four CBT interventions (randomized)
Number of subjects: 2300
Study: 37516165

Group type: EXPERIMENTAL
Intervention: Telephone disclosure by a Board-certified genetic counselor
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Online self-guided modality with optional genetic counselor follow-up via telephone
Number of subjects: 4000
Study: 37516299

Group type: EXPERIMENTAL
Intervention: eGFR calculated using 2 markers (creatinine and cystatin C)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: eGFR calculated using 6 different equations based on creatinine; 3 based on creatinine and cystatin C combined; and 2 based on panels of markers including creatinine, cystatin C, β-trace protein (BTP)
Number of subjects: 106
Study: 37516398

Group type: EXPERIMENTAL
Intervention: High central sensitization score (>5/10)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low central sensitization score (<5/10)
Number of subjects: 53
Study: 37516818

Group type: EXPERIMENTAL
Intervention: EGFR TKI treatment
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Presence of SNPs in HLA-DRB5 gene
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Presence of SNPs in KIR3DL1 and KIR3DL2 genes
Number of subjects: 135
Study: 37516830

Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 27
Study: 37516835

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HFSRT) - 6 - 7 × 5 Gy prescribed to the surrounding isodose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single fraction stereotactic radiosurgery (SRS) - 1 × 12-20 Gy prescribed to the surrounding isodose
Number of subjects: 0
Study: 37516837

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) from a universal donor (n=5)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Autologous FMT (n=6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 11
Study: 37516841

Group type: EXPERIMENTAL
Intervention: Maternal probiotics
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 202
Study: 37516867

Group type: EXPERIMENTAL
Intervention: UCPVax vaccine at 0.5 mg subcutaneously combined with atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Number of subjects: 0
Study: 37516873

Group type: EXPERIMENTAL
Intervention: REAtouch virtual device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 37517006

Group type: EXPERIMENTAL
Intervention: Sitting Balance Scale (SBS-T)
Number of subjects: 60
Study: 37517037

Group type: EXPERIMENTAL
Intervention: Vestibular function tests (caloric tests, cVEMP, oVEMP, vHIT, SOT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Dizziness handicap inventory (DHI) and visual analogue scale for vertigo (VAS-V)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pure-tone audiometry (PTA)
Number of subjects: 86
Study: 37517110

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 171
Study: 37517327

Group type: EXPERIMENTAL
Intervention: Measured GFR (mGFR) based on iohexol plasma clearance
Number of subjects: 96
Study: 37517413

Group type: EXPERIMENTAL
Intervention: Momelotinib (200 mg orally once per day)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Danazol (300 mg orally twice per day)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 195
Study: 37517422

Group type: EXPERIMENTAL
Intervention: OVX836 180 μg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: OVX836 300 μg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: OVX836 480 μg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 37517452

Group type: EXPERIMENTAL
Intervention: Metabolite biomarkers identified through metabolomics profiling and liquid chromatography-mass spectrometry tests.
Number of subjects: 1024
Study: 37517552

Group type: EXPERIMENTAL
Intervention: Donor human milk (DHM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Early preterm human milk
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mature preterm human milk
Number of subjects: 15
Study: 37517579

Group type: EXPERIMENTAL
Intervention: Stent placement with best medical therapy (BMT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 63
Study: 37517614

Group type: COMPARATOR
Intervention: Preterm infants
Number of subjects: 102

Group type: COMPARATOR
Intervention: Covarying network of gut microbiota
Number of subjects: 102

Group type: COMPARATOR
Intervention: Clostridium_sensu_stricto_1
Number of subjects: 102
Study: 37517799

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of choroidal hypertransmission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of ELM disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of OPL/INL subsidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of hyporeflective wedge-shaped band
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative measurement of choroidal hypertransmission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative measurement of RPE attenuation/disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal changes for choroidal hypertransmission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal changes for ELM disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal changes for EZ disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal changes for RPE attenuation/disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall ability to evaluate changes over time for specific features of iRORA and cRORA
Number of subjects: 0
Study: 37517825

Group type: EXPERIMENTAL
Intervention: Genomic assay methodology and reporting from 95 reports describing 113 assay results.
Number of subjects: 56
Study: 37517875

Group type: EXPERIMENTAL
Intervention: RRMM treatments
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Hospital visits
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Caregiver presence
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Transportation costs
Number of subjects: 276
Study: 37518058

Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein (1.2 g/kg/day) starting from ICU day 5 until ICU discharge or ICU day 90
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Standard enteral nutrition formula (0.8-1.2 g/kg/day) without supplemental protein
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Both groups receive primary enteral formula with a maximum protein of 1.2 g/kg/day
Number of subjects: 2502
Study: 37518060

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg QD on days 1-4; Gefitinib 250 mg QD on days 5-15, combined with Apatinib 500 mg QD on days 12-15.
Number of subjects: 22
Study: 37518076

Group type: EXPERIMENTAL
Intervention: High-dose docosahexaenoic acid (DHA) enteral supplementation during the neonatal period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose DHA enteral supplementation
Number of subjects: 0
Study: 37518082

Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) - 2 weekly sessions for 10 weeks using virtual reality glasses to project OKS at a preset speed.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo treatment - virtual reality video without OKS.
Number of subjects: 102
Study: 37518089

Group type: EXPERIMENTAL
Intervention: Colistin administered as colistin methanesulfonate (CMS) intravenously at standard dosing.
Number of subjects: 30

Group type: COMPARATOR
Intervention: No ECMO (control group).
Number of subjects: 30